Hyperion Therapeutics Secures $60,000,000 Series C Funding

  • Feed Type
  • Date
    7/5/2009
  • Company Name
    Hyperion Therapeutics
  • Mailing Address
    601 Gateway Blvd South San Francisco, CA 94080
  • Company Description
    Hyperion Therapeutics, Inc. is a privately held specialty biopharmaceutical company dedicated to improving patients’ lives through the development and commercialization of therapies that address critical unmet needs and underserved patient populations. The Company’s initial efforts are focused in the areas of gastroenterology and hepatology.
  • Website
    http://www.hyperiontx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $60,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The capital will fund the Phase III clinical program for UCD as well as a Phase II study in low grade hepatic encephalopathy.
  • M&A Terms
  • Venture Investor
    Bay City Capital
  • Venture Investor
    Panorama Capital
  • Venture Investor
    Highland Capital Partners
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Sofinnova Ventures

By posting a comment, you agree to our terms and conditions.